Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical Center, 525 East 68th Street, New York, NY 10065, USA.
Cardiology Division, New York Presbyterian Hospital, Weill Cornell Medical Center, Starr Pavilion, 520 East 70th Street, 4th Fl, New York, NY 10021, USA.
Cardiol Clin. 2019 Nov;37(4):441-447. doi: 10.1016/j.ccl.2019.07.009.
Left ventricular systolic dysfunction (LVSD) and overt heart failure are well known manifestations of chemotherapy-induced cardiotoxicity. The development of LVSD is clinically significant because it can impact the delivery of lifesaving chemotherapy and increase the risk of developing heart failure, compromising quality of life and survival years after cure of the cancer. Cancer treatment-related cardiomyopathy is most commonly associated with anthracyclines and trastuzumab. Several interventions have been identified to prevent cancer-induced cardiomyopathy. Anthracyclines is a major culprit, and prevention strategies with limiting cumulative dose, continuous infusion, dexrazoxane, and liposomal formulation have been shown to decrease the risk of cardiotoxicity.
左心室收缩功能障碍（LVSD）和明显心力衰竭是化疗引起的心脏毒性的已知表现。LVSD 的发展具有重要的临床意义，因为它会影响挽救生命的化疗药物的输送，并增加心力衰竭的风险，在癌症治愈多年后影响生活质量和生存时间。癌症治疗相关的心肌病最常与蒽环类药物和曲妥珠单抗有关。已经确定了几种干预措施来预防癌症引起的心肌病。蒽环类药物是主要的罪魁祸首，通过限制累积剂量、连续输注、右雷佐生和脂质体制剂等预防策略已被证明可以降低心脏毒性的风险。
